<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

October 7, 2020

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Therapeutics, Inc. announced that it has dosed the first patient in its phase II study of istaroxime in patients experiencing early cardiogenic shock. Early cardiogenic shock is one of two developmental programs for istaroxime, with the other program targeting acute heart failure, which is supported by positive phase IIOa and IIb trial results and a FDA Fast Track designation. Fast Track programs put an extra strain on clinical trials logistics, but Yourway is prepared for such challenges.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat
Come chat with us!
Hello! How can I help you?